Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)